3 Growth Companies On KRX With Insider Ownership And Up To 64% Revenue Growth

Simply Wall St · 10/14 21:01

The South Korean market has shown stability, remaining flat over the last week and posting a 3.8% increase over the past year, with earnings projected to grow by 30% annually. In this environment, identifying growth companies with significant insider ownership can be crucial as these stocks often align management interests with shareholder value and may capitalize on favorable market conditions.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name Insider Ownership Earnings Growth
People & Technology (KOSDAQ:A137400) 16.4% 35.6%
Seojin SystemLtd (KOSDAQ:A178320) 30.8% 49.1%
Bioneer (KOSDAQ:A064550) 15.8% 97.6%
Oscotec (KOSDAQ:A039200) 26.1% 122%
HANA Micron (KOSDAQ:A067310) 18.3% 105.8%
Park Systems (KOSDAQ:A140860) 33% 34.6%
Vuno (KOSDAQ:A338220) 19.4% 110.9%
UTI (KOSDAQ:A179900) 33.1% 134.6%
Techwing (KOSDAQ:A089030) 18.7% 83.6%
INTEKPLUS (KOSDAQ:A064290) 16.3% 96.7%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.11 trillion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 billion.

Insider Ownership: 26.6%

Revenue Growth Forecast: 64.2% p.a.

ALTEOGEN is forecast to experience significant growth, with revenue expected to increase 64.2% annually, surpassing the South Korean market average. The company is anticipated to become profitable within three years, with earnings projected to grow 99.46% per year and a high return on equity of 66.3%. Currently trading at 71% below estimated fair value, ALTEOGEN presents potential for strong growth despite recent shareholder dilution and lack of substantial insider buying or selling activity recently.

KOSDAQ:A196170 Ownership Breakdown as at Oct 2024
KOSDAQ:A196170 Ownership Breakdown as at Oct 2024

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc. is a biotech research company specializing in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.99 trillion.

Operations: The company's revenue segment primarily comprises biotechnology startups, generating ₩32.95 billion.

Insider Ownership: 30.5%

Revenue Growth Forecast: 24.7% p.a.

ABL Bio is positioned for substantial growth, with its revenue projected to expand at 24.7% annually, outpacing the South Korean market average. The company is expected to achieve profitability within three years, reflecting above-average market growth. Despite a highly volatile share price recently and a forecasted low return on equity of 13%, ABL Bio's potential for rapid revenue increase remains compelling, with no significant insider trading activity in the past three months.

KOSDAQ:A298380 Ownership Breakdown as at Oct 2024
KOSDAQ:A298380 Ownership Breakdown as at Oct 2024

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management, with a market cap of ₩7.68 trillion.

Operations: The company's revenue segments include Label at ₩1.28 trillion, Platform at ₩361.12 billion, and Solution at ₩1.24 trillion.

Insider Ownership: 32.5%

Revenue Growth Forecast: 14.0% p.a.

HYBE's growth prospects are strong, with earnings expected to rise significantly at 42.6% annually, surpassing the South Korean market average. Despite recent financial challenges, including a substantial drop in net income and earnings per share compared to last year, revenue is forecasted to grow faster than the market at 14% annually. The company has completed a share buyback of KRW 26.09 billion for price stabilization and trades below its estimated fair value by 22%.

KOSE:A352820 Earnings and Revenue Growth as at Oct 2024
KOSE:A352820 Earnings and Revenue Growth as at Oct 2024

Turning Ideas Into Actions

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.